文献速递前列腺癌

精液标志物组合sTWEAK与exomiR-221-3p/222-3p用于前列腺癌预后诊断及主动监测升级检测

A Semen Panel Signature Comprising sTWEAK Cytokine Levels and Expression of exomiR-221-3p and exomiR-222-3p for Assessing Prostate Cancer Prognosis, Diagnostic Utility, and Detection of Upgrading During Active Surveillance.
PubMed 文献 · J Urol · 2025-08-27

研究评估精液生物标志物组合(sTWEAK、exomiR-221-3p、exomiR-222-3p)在前列腺癌诊断、肿瘤侵袭性预后(ISUP分级和生化复发)以及主动监测中确认活检升级识别方面的价值。纳入136例前列腺癌患者、20例健康对照、35例活检阴性患者和51例主动监测低风险患者,采用ELISA和exovesicle表达检测。sTWEAK联合exomiR-221-3p模型预测高风险前列腺癌AUC=0.937;sTWEAK单独区分前列腺癌AUC=0.897;sTWEAK联合阳性活检核心百分比预测主动监测升级AUC=0.824。

要点

  • sTWEAK联合exomiR-221-3p预测高风险前列腺癌AUC达0.937。
  • sTWEAK单独区分前列腺癌AUC为0.897。
  • sTWEAK联合阳性活检核心百分比预测主动监测升级AUC为0.824。

核心结论

  • sTWEAK与exomiR-221-3p联合临床参数可作为前列腺癌诊断、主动监测升级和生化复发预后的预测工具。

研究设计与样本

  • 研究纳入136例前列腺癌患者(低风险ISUP I-II 85例,高风险ISUP≥III 51例)、20例健康对照、35例活检阴性患者和51例主动监测低风险前列腺癌患者。
  • 采用ELISA定量精液sTWEAK水平,并检测精液exovesicle中exomiR-221-3p和exomiR-222-3p的相对表达水平。
  • 统计方法包括多因素二元logistic回归、Cox多因素回归、生存分类回归树模型和ROC等。

主要发现

  • sTWEAK联合exomiR-221-3p模型预测高风险前列腺癌的AUC=0.937,生物标志物与概率呈线性关系但无明确截断值。
  • PSA密度联合sTWEAK模型可用于预测生化复发。
  • sTWEAK单独区分前列腺癌的AUC=0.897。
  • 在主动监测患者中,sTWEAK水平联合阳性活检核心百分比预测升级的AUC=0.824。

关键数值与推荐

  • 预测高风险前列腺癌:sTWEAK联合exomiR-221-3p模型AUC=0.937。
  • 区分前列腺癌:sTWEAK单独AUC=0.897。
  • 预测主动监测升级:sTWEAK联合阳性活检核心百分比AUC=0.824。

临床怎么用

  • 精液标志物组合sTWEAK和exomiR-221-3p可用于辅助前列腺癌诊断和高风险评估。
  • sTWEAK联合阳性活检核心百分比有助于识别主动监测中的活检升级。
  • PSA密度联合sTWEAK模型可用于生化复发风险预测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We evaluated the seminal biomarker signature (sTWEAK, exomiR-221-3p, and exomiR-222-3p) in several prostate cancer (PCa) settings: diagnosis, tumor aggressiveness prognosis (International Society of Urological Pathology [ISUP] grade in radical prostatectomy specimens and biochemical recurrence [BCR]), and identifying biopsy upgrading in confirmatory biopsies during active surveillance (AS). MATERIALS AND METHODS: Semen samples were collected from 136 PCa patients classified by prostatectomy specimen ISUP grades and classified as low-risk (ISUP I-II, n = 85) and high-risk patients (ISUP ≥III, n = 51), along with 20 healthy controls, 35 patients with negative biopsies, and 51 low-risk PCa patients under AS. The relative expression levels of exomiR-221-3p and exomiR-222-3p in semen exovesicles were measured. ELISA was used to quantify sTWEAK levels. Statistical analyses, including multivariable binary logistic, Cox multivariate regression analysis, Survival classification regression tree models, and ROC, among others, were used to evaluate the predictive value of the biomarkers. RESULTS: A model combining sTWEAK and exomiR-221-3p predicted high-risk PCa (AUC = 0.937), showing a linear biomarker-probability relationship but no clear cutoff. A model comprising PSA density and sTWEAK could be used for predicting BCR. sTWEAK alone distinguished PCa cases (AUC = 0.897). In AS patients, sTWEAK levels plus the percentage of positive biopsy cores best predicted upgrading (AUC = 0.824). CONCLUSIONS: Incorporating sTWEAK and exomiR-221-3p, along with clinical parameters, offers a promising diagnostic panel for PCa and serves as a useful predictive tool for AS upgrading and BCR prognosis.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Alves-Santiago M, Altuna-Coy A, López-Ribelles P, et al. A Semen Panel Signature Comprising sTWEAK Cytokine Levels and Expression of exomiR-221-3p and exomiR-222-3p for Assessing Prostate Cancer Prognosis, Diagnostic Utility, and Detection of Upgrading During Active Surveillance. J Urol. 2025. PMID: 40863180. doi:10.1097/JU.0000000000004749

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。